Barbara Bispham is an associate in the firm’s Business Law Department and a member of its nationally recognized Technology and Life Sciences group. Ms. Bispham regularly represents issuers, investment banks, and financial institutions in connection with initial and follow-on public offerings, shelf registrations, at the market offerings, private equity transactions, and private placements of equity securities. In addition to a robust domestic practice, Ms. Bispham has significant experience in transactions involving foreign issuers seeking to access the U.S. capital markets. Ms. Bispham also counsels both domestic and foreign issuers with respect to corporate governance, SEC reporting, and securities law compliance. She advises private companies on a wide range of general corporate and securities matters across their entire life cycle, including formation, capital raising, and strategic partnerships. Ms. Bispham’s experience extends to a variety of industries, with a focus on life sciences.





Ms. Bispham’s recent representations include:

  • argenx SE on its $345.7 million follow-on public offering
  • Axcella Health Inc. on its $71.4 million initial public offering
  • BridgeBio Pharma, Inc. on its $400.8 million initial public offering
  • Cabaletta Bio, Inc. on its $74.8 million initial public offering
  • Deciphera Pharmaceuticals, Inc. on its $400.0 million follow-on offering
  • UroGen Pharma Ltd. on its $66.9 million initial public offering*
  • UroGen Pharma Ltd. on its $64.9 million follow-on public offering*
  • The underwriters in the $134.9 million follow-on public offering for Ascendis Pharma A/S*
  • The underwriters in the $155.4 million initial public offering for Genfit S.A.
  • The underwriters in the $89.9 million initial public offering for Zealand Pharma A/S*
  • The underwriters in the $57.5 million initial public offering of Syros Pharmaceuticals, Inc.*

* Denotes experience prior to joining Goodwin

Professional Experience

Prior to joining Goodwin, Ms. Bispham was an associate in the New York office of Cooley LLP.


In law school, Ms. Bispham served as managing editor of the Cornell International Law Journal.

In The News









J.D., 2011
Cornell Law School
B.A., 2008
University of Pennsylvania
(magna cum laude, with honors)



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique